Tirzepatide · 3 min read
The shortage that made mass compounding legal ended in late 2024. What survived — the narrow 503A pathway, the litigation, the FDA's 2026 enforcement wave — and what it means if you're buying.
The shortage that made mass compounding legal ended in late 2024. What survived — the narrow 503A pathway, the litigation, the FDA's 2026 enforcement wave — and what it means if you're buying.
The one-sentence answer: brand tirzepatide (Mounjaro, Zepbound) is fully legal by prescription; mass-market compounded tirzepatide lost its broad legal basis when the FDA declared the shortage resolved in late 2024, and the programs still selling it in 2026 operate through narrower, contested pathways under active FDA enforcement pressure. Anyone who tells you the answer is a clean yes or a clean no is selling something.
Compounding law allows pharmacies to prepare copies of an FDA-approved drug when that drug is on the FDA shortage list. Tirzepatide entered shortage in 2022, and an entire telehealth economy grew in the gap. The FDA declared the shortage resolved in October 2024 and reaffirmed it that December after review; grace periods then ended — state-licensed 503A pharmacies were expected to stop compounding "essentially copies" by early 2025, and large 503B outsourcing facilities by March 19, 2025. The Outsourcing Facilities Association sued to overturn the shortage determination; the enforcement timeline held up in court, and litigation has continued without restoring the broad window.
Section 503A has always permitted patient-specific compounding for a documented clinical need the approved product cannot meet — a verified allergy to an inactive ingredient, for example, or a clinically justified dose or form the manufacturer does not make. That pathway survived, and it is the legal theory under which most 2026 programs operate: patient-specific prescriptions, often for "personalized" doses or formulations. The FDA has been explicit that convenience, cost, or preference is not clinical need, and that adding vitamins or additives does not automatically make a compound legitimately different — by fall 2025 more than 80% of compounded GLP-1 weight-loss preparations mixed in B12 or amino acids, and a 2026 analysis identified a novel tirzepatide-B12 adduct in such products that exists in no approved drug. In April 2026 the FDA went further, proposing to formally exclude tirzepatide, semaglutide, and liraglutide from the 503B bulks list.
February 2026 brought a wave of roughly thirty FDA warning letters to telehealth companies over compounded GLP-1 marketing — particularly claims implying FDA approval or equivalence. Federal scrutiny of major telehealth players escalated, including a Department of Justice referral involving Hims & Hers, which closed its compounded GLP-1 program to new patients and went brand-only for new starts in March 2026. Several large programs in our database pivoted to brand fulfillment entirely (Ro, Hims & Hers, WeightWatchers Clinic). Others continue compounded sales under the patient-specific theory. Enforcement is real but uneven, state boards add their own layer, and the picture can change with a single court ruling — which is exactly why we date every price and every claim.
Three practical translations. First, you are not the enforcement target — FDA actions run against pharmacies and sellers, not patients — but you carry the product risk: compounded drugs are not FDA-reviewed for safety, effectiveness, or quality, and quality now varies by pharmacy more than ever. Second, prepayment risk is regulatory risk: a twelve-month prepaid compounded plan is a bet that the program outlives the litigation cycle; read refund terms before committing (our prepaid analysis prices the trade-off). Third, the brand alternative got cheap enough to compare honestly: Zepbound at $299–$449 through LillyDirect, around $350 on TrumpRx, and roughly a $50 copay for newly eligible Medicare patients since mid-2026 — the gap a compounded program must justify is a few hundred dollars a month, not a thousand. Ask any compounded program three questions: which pharmacy fills the prescription, what the clinical-need documentation is, and what happens to your money if regulation interrupts the program.
This is consumer research on a moving regulatory target, current to our publication date — not legal advice, and not a prediction. We correct and date-stamp changes; see corrections.
Mass-market compounding lost its legal basis when the FDA shortage resolution took full effect in early 2025. Patient-specific compounding for documented clinical need remains lawful under Section 503A, which is the contested pathway most 2026 programs rely on — under active FDA enforcement pressure.
FDA enforcement targets compounders and sellers, not patients. Your exposure is product risk (no FDA review of the preparation) and financial risk (programs interrupted by enforcement or litigation), not legal jeopardy.
They operate under the patient-specific/personalization theory of Section 503A, which the FDA disputes in many applications but which enforcement has addressed unevenly. Several large players (Hims & Hers, Ro) exited compounding for new patients in 2026; dozens of smaller programs continue.
The FDA's April 2026 proposed rule would exclude tirzepatide from the 503B bulks list, further narrowing large-scale compounding, and litigation continues. The patient-specific 503A pathway is harder to eliminate entirely, but the space is contracting, not expanding.